Sugi Predict

Sugi Predict / Compounds / SCHEMBL2736632

SCHEMBL2736632

SCHEMBL2736632

CCO/N=C(\C)c1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.74
▸ L3MBTL1 Q9Y468 2/20 0.74
▸ MAPK1 P28482 1/20 0.74
▸ HTT P42858 1/20 0.74
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ NPC1 O15118 2/20 0.53
▸ RAB9A P51151 2/20 0.53
▸ HPGD P15428 1/20 0.51
▸ PPARA Q07869 4/20 0.50
▸ PTBP1 P26599 1/20 0.48
▸ MAPT P10636 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ PPARG P37231 4/20 0.45
▸ PKM P14618 1/20 0.44
▸ CDK5 Q00535 1/20 0.44
▸ CDK5R1 Q15078 1/20 0.44
▸ DRD4 P21917 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23635710 1.00 LMNA (0.74) LMNAL3MBTL1MAPK1HTTSMN1; SMN2
SCHEMBL22952897 0.84 LMNA (0.69) LMNAL3MBTL1MAPK1HTTSMN1; SMN2
SCHEMBL13683674 0.82 SMN1; SMN2 (0.52) LMNAL3MBTL1MAPK1HTTSMN1; SMN2
SCHEMBL28581122 0.81 L3MBTL1 (0.65) LMNAL3MBTL1MAPK1HTTSMN1; SMN2
SCHEMBL13351521 0.81 ALDH1A1 (0.49) LMNAL3MBTL1MAPK1HTTSMN1; SMN2
SCHEMBL4451421 0.80 L3MBTL1 (0.71) LMNAL3MBTL1MAPK1HTTSMN1; SMN2
SCHEMBL19733323 0.80 L3MBTL1 (0.71) LMNAL3MBTL1MAPK1HTTSMN1; SMN2
SCHEMBL4476864 0.80 LMNA (0.69) LMNAL3MBTL1MAPK1HTTSMN1; SMN2
SCHEMBL4476867 0.80 LMNA (0.69) LMNAL3MBTL1MAPK1HTTSMN1; SMN2
SCHEMBL5958328 0.80 LMNA (0.48) LMNAL3MBTL1MAPK1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020133091-A1 PYRIDYLOXY CARBOXYLATE DERIVATIVE, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF 青岛清原化合物有限公司 2020-07-02 — — WO disclosed
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 — — US disclosed
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 — — US disclosed
US-20110118450-A1 ACCELERANTS FOR THE MODIFICATION OF NON-NATURAL AMINO ACIDS AND NON-NATURAL AMINO ACID POLYPEPTIDES AMBRX, INC. (US) 2011-05-19 — — US disclosed
US-7888533-B2 Formation of oxime-containing compounds from reaction of carbonyl, hydroxylamine and bifunctional aromatic amines; incorporated into growth hormone AMBRX, INC. (US) 2011-02-15 — — US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 — — US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 — — US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 — — US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 — — US disclosed
EP-2130820-A1 Antipruritics SHIONOGI & CO., LTD. (JP) 2009-12-09 — — EP disclosed
EP-1477186-B1 ANTIPRURITICS SHIONOGI & CO (JP) 2009-11-11 — — EP disclosed
US-20080312292-A1 Antipruritics YASUI KIYOSHI 2008-12-18 — — US disclosed
US-20080312292-A1 Antipruritics YASUI KIYOSHI 2008-12-18 — — US disclosed
US-20080154058-A1 Accelerants for the Modification of Non-Natural Amino Acids and Non-Natural Amino Acid Polypeptides AMBRX, INC. (US) 2008-06-26 — — US disclosed
US-20070027144-A1 Novel use of cannabinoid receptor agonist SHIONOGI & CO., LTD. (JP) 2007-02-01 — — US disclosed
US-20070027144-A1 Novel use of cannabinoid receptor agonist SHIONOGI & CO., LTD. (JP) 2007-02-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027144-A1 Novel use of cannabinoid receptor agonist CNR2, CNR1, OPRM1 LMNA 4495/4885L3MBTL1 2630/4885MAPK1 1638/4885
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter CNR2, CNR1, NPY2R LMNA 3511/4885L3MBTL1 4225/4885MAPK1 1238/4885
US-20080154058-A1 Accelerants for the Modification of Non-Natural Amino Acids and Non-Natural Amino Acid Polypeptides DNPEP, DAO, AADAT LMNA 2010/4885L3MBTL1 2344/4885MAPK1 2626/4885
US-20110118450-A1 ACCELERANTS FOR THE MODIFICATION OF NON-NATURAL AMINO ACIDS AND NON-NATURAL AMINO ACID POLYPEPTIDES DNPEP, DAO, AADAT LMNA 2010/4885L3MBTL1 2344/4885MAPK1 2626/4885
US-20080312292-A1 Antipruritics CNR1, CNR2, OPRL1 LMNA 4604/4885L3MBTL1 3630/4885MAPK1 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.